RoActemra® (tocilizumab) has been launched as a specific treatment option for pJIA, the form of juvenile arthritis with the worst prognosis.1 This decision heralds a less frequent dosing regimen than currently available treatments for many of the estimated one thousand plus children1 who have failed with methotrexate (MTX) and whose childhood could be affected by pJIA, which can make simple, everyday activities such as walking and playing with friends both painful and challenging.
No comments:
Post a Comment